{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-061375","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.293283+00:00","generated_at":"2026-05-19T00:11:33.420770+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Positive Phase 1b firmonertinib data; 16.0 mo mPFS at 240 mg; global Phase 3 ALPACCA planned H2 2025","bullets":["16.0 months median PFS by BICR at 240 mg dose in first-line EGFR PACC mutant NSCLC; 68.2% confirmed ORR at 240 mg.","41% (7/17) confirmed CNS complete response; 53% CNS ORR in CNS-evaluable patients by BICR.","Safety consistent with prior data: no Grade 4/5 TRAEs, no discontinuations due to TRAEs; most common TRAEs diarrhea, elevated liver enzymes, rash.","Firmonertinib 240 mg selected for pivotal Phase 3; ALPACCA trial enrollment expected to start H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-061375","json":"https://secwatch.observer/filing/0001104659-25-061375.json","markdown":"https://secwatch.observer/filing/0001104659-25-061375.md","text":"https://secwatch.observer/filing/0001104659-25-061375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925061375/0001104659-25-061375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925061375/tm2518615d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T00:11:33.420770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}